| Stuart Charles Goldstein, | |
|
1010 Ranch Rd, Moscow, ID 83843-7484 | |
| (208) 310-2125 | |
| Not Available |
| Full Name | Stuart Charles Goldstein |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Public Health & General Preventive Medicine |
| Location | 1010 Ranch Rd, Moscow, Idaho |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013674837 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083P0901X | Preventive Medicine - Public Health & General Preventive Medicine | M-6713 (Idaho) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Stuart Charles Goldstein, 1010 Ranch Rd, Moscow, ID 83843-7484 Ph: (208) 310-2125 | Stuart Charles Goldstein, 1010 Ranch Rd, Moscow, ID 83843-7484 Ph: (208) 310-2125 |
News Archive
Colorado policymakers are wrestling to bring the burgeoning Medicaid budget under control, as critics fear health insurance for the poor will consume the state budget. But even the smallest cuts or cost-shares raise protests from patient advocates and objections that such measures will prove more expensive in the long run.
Radio Australia examines the Global Fund to Fight AIDS, Tuberculosis and Malaria's push for more funding from Australia and China. Global Fund Executive Director "Michel Kazatchkine is currently touring the world's capitals seeking renewed government pledges to build on an already impressive record and as well as looking to Australia to do more, he's hoping soon to get China to become not just recipient, but donor."
The inventors of a new and unique cancer immunotherapy developed at Roswell Park Comprehensive Cancer Center have announced a major step forward with that therapy, known as SurVaxM. MimiVax LLC principals Robert Fenstermaker, MD, and Michael Ciesielski, PhD, have announced that the company, spun off from Roswell Park in 2012, has entered into a China-exclusive licensing agreement for SurVaxM with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical Co. Ltd. based in Shanghai, China.
Premature babies are at an increased risk for developing autism spectrum disorder. But a small study indicates that preemies who avoid eye contact in early infancy are less likely to demonstrate symptoms of autism at age 2 than preemies who maintain eye contact during early interactions, according to new research at Washington University School of Medicine in St. Louis.
Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced efficacy and safety data from the BRIM3 trial, a large, randomized, multi-center Phase 3 clinical study of vemurafenib in patients with previously untreated metastatic melanoma with the BRAFV600 mutation.
› Verified 4 days ago